Lv11
60 积分 2022-08-01 加入
The Lancet Commission on prostate cancer: planning for the surge in cases
2小时前
待确认
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
6天前
已完结
Optimism Surrounds Claudin 18.2 ADC
26天前
已完结
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
2个月前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
2个月前
已完结
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
2个月前
已完结
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
2个月前
已完结
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
2个月前
已完结
Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies
4个月前
已完结
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
4个月前
已完结
皖公网安备34019202002308
